Form 4: IQVIA Holdings Executive Acquires Shares and Stock Appreciation Rights Following Performance Milestone

Bhavik Patel, President of Commercial Solutions at IQVIA Holdings, acquired shares and stock appreciation rights after performance conditions were met.

Summary

• Bhavik Patel, an officer at IQVIA Holdings, acquired 1,299 shares of common stock on January 28, 2025, as a result of performance-based restricted stock units granted in 2022.
• These shares were acquired at a price of $0, indicating they were awarded rather than purchased.
• Additionally, 612 shares were disposed of at a price of $203.43 per share, likely to cover tax obligations.
• Mr. Patel also acquired 10,534 stock appreciation rights (SARs) with an exercise price of $203.43, which vest in three annual installments starting January 28, 2026.
• The performance conditions for the restricted stock units were determined to have been satisfied by the company's Leadership Development and Compensation Committee on January 28, 2025.

Sentiment

Score: 7

Explanation: The document reflects a positive event (performance goals met) and standard executive compensation practices. The disposal of shares is likely for tax purposes and not a negative signal.

Positives

• The vesting of performance-based restricted stock units indicates that performance goals were met, which is a positive sign for the company.
• The acquisition of stock appreciation rights provides an incentive for future performance.

Negatives

• The disposal of 612 shares, while likely for tax purposes, could be perceived as a slight negative if not understood in context.

Risks

• The value of the stock appreciation rights is dependent on the future performance of the company's stock price.
• There is a risk that the stock price could decline, reducing the value of the SARs.

Future Outlook

The stock appreciation rights vest in three annual installments beginning on January 28, 2026, incentivizing future performance.

Management Comments

• The performance conditions applicable to the awards were determined to have been satisfied by the Company's Leadership Development and Compensation Committee on January 28, 2025.

Industry Context

This filing is a routine disclosure of executive compensation and is typical for publicly traded companies. It reflects the company's compensation strategy to align executive interests with company performance.

Comparison to Industry Standards

• The use of performance-based restricted stock units and stock appreciation rights is a common practice in the pharmaceutical and healthcare technology industries, aligning executive compensation with company performance.
• Companies like Veeva Systems and Medidata Solutions also use similar equity-based compensation plans for their executives.
• The vesting schedule of the SARs is also typical, with a three-year vesting period being a common practice.

Stakeholder Impact

• Shareholders may view the vesting of performance-based awards as a positive sign of company performance.
• Employees may see this as a positive sign of the company's commitment to rewarding performance.

Next Steps

• The stock appreciation rights will vest in three annual installments starting January 28, 2026.

Key Dates

Keywords

IQVIA, stock appreciation rights, performance-based restricted stock units, executive compensation, Bhavik Patel, insider trading, SEC Form 4